Tenders Are Invited For Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accord ... in Germany

Work Detail

Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130C Paragraph 1 Sgb V / Section 130A Paragraph 8 Sgb V For Medicines With The Active Ingredient Cladribine (Atc: L04aa40).. The Aok Niedersachsen Offers The Active Ingredient Cladribine (Atc: L04aa40). The Health Insurance Company Offers Discount Contracts To All Interested Pharmaceutical Companies Without A Selection Decision For The Period Up To The Entry Into Force Of Exclusive Contracts As A Result Of A Formal Award Procedure In Accordance With The Regulations Of Part 4 Of The Gwb. The Contracts Are Concluded As Part Of An “Open-House Model” And Are Not Exclusive; Aok Lower Saxony Wants Contracts With All Market Participants (Pharmaceutical Companies). In The Open-House Model, Uniform Conditions Apply To All Participants. Contract Contents, Conditions And Access Procedures Are Uniform - Individual Negotiations Are Generally Not Carried Out. The Contract Terms Are A Maximum Of Twenty-Four Months; The Earliest Contract Start Date Is March 1, 2026. All Contracts End On February 29, 2028 At The Latest, Regardless Of The Date Of Conclusion Of The Respective Contract. Joining Or Concluding A Contract Can Take Place On The First Of Each Month Within The Twenty-Four Month Period. There Is A Right Of Termination Six Weeks To The End Of The Month. The Aok Lower Saxony. The Health Insurance Fund Reserves The Right To Replace The Non-Exclusive Open-House Discount Agreements With Exclusive Discount Agreements During The Contract Term. When Advertised, Exclusive Discount Contracts Come Into Force, The Open-House Contracts Will Be Terminated In Accordance With The Contractual Regulations, I.E. H. The Open-House Contracts End Automatically. According To Aok Niedersachsens Experience, Exclusive Discount Agreements Usually Come Into Force Six To Eight Months After The Publication Of The Corresponding Tender Notice In The Supplement To The Official Journal Of The European Union. The Future Contractual Partners In The Open-House Model Are Requested To Regularly Consult The Supplement To The Official Journal Of The European Union Regarding These Tender Notices. Interested Pharmaceutical Companies Can Request The Contract Documents And The Contract Conditions At The Contact Address Mentioned Under I.1). Contracts For The Active Ingredient Cladribine (Atc: L04aa40) Will Be Concluded For The First Time With Effect From March 1, 2026. Interested Parties Who Would Like To Become Contractual Partners On This Date Must Submit The Contractual Documents To The Address Specified In The Contractual Documents By January 30, 2026. It Depends On Access To Aok Niedersachsen. Later Contracts Are Possible During The Twenty-Four-Month Maximum Term On The First Of Each Month. From An Organizational Point Of View, The Aok Generally Needs A Lead Time Of 35 Calendar Days To Carry Out The Necessary Work, E.G. B. To Be Able To Ensure Contract Reporting In The Lauer-Taxe®. The Exact Deadlines For Receipt Will Be Announced With The Contract Documents. This Publication Does Not Involve The Awarding Of A Public Award

Contact Information